About OmniCarta™
Our Vision and Mission
At OmniCarta™, we aim to redefine preclinical drug safety and efficacy assessment through innovation and advanced technologies. Our platform integrates multiple sophisticated techniques to provide an unparalleled understanding of drug effects at whole organism scale.
Who We Are
A team with unrivalled experience in pre-clinical cell-based assays
Professor Andrew Filby, our CEO and founder has over 25 years experience in both flow and imaging cytometry, working within both academia and industry.
Dr Saimir Luli, our CTO, has over 15 years experience in pre-clinical imaging and novel probe design.
Professor Gavin Richardson, our CSO, is a highly experienced researcher in cardiology and senescence. He ha a proven track record of utilising cutting-edge analysis technologies in his research.
Dr David McDonald, our Director of Analytical Platforms, has over 20 years of immunological and cytometry experience. He runs one of the most successful core platforms in single cell analysis technologies in the world.
Bethany Hunter, our Director of Tissue Analytics has over 10 years of experience in cutting edge histology techniques.
Dr Rachel Redgrave, our Director of Pre-Clinical Biology and has vast experience in small animal models.
Professor Paul Rees, our Director of Informatics, is an expert in computer vision techniques for image analysis.
Join Us in Innovation
Partner with us to enhance drug research and development capabilities. Together, we can innovate and transform the landscape of pharmaceuticals.